SpringWorks Therapeutics to Report First Quarter 2024 Financial Results Thursday, May 2, 2024
18 Aprile 2024 - 1:00PM
SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage
biopharmaceutical company focused on severe rare diseases and
cancer, today announced that it will host a live conference call
and webcast at 8:30 a.m. E.T. on Thursday, May 2, 2024 to report
its first quarter financial results and discuss recent business
updates.
To join the live webcast and view the corresponding slides,
please click here. To access the live call by phone, please
pre-register for the call by clicking here. Once registration is
complete, participants will be provided with a dial-in number and
conference code to access the call. A replay of the webcast will be
available for a limited time following the event on the Investors
and Media section of the Company’s website at
https://ir.springworkstx.com.
About SpringWorks Therapeutics
SpringWorks is a commercial-stage biopharmaceutical company
applying a precision medicine approach to developing and delivering
life-changing medicines for people with severe rare diseases and
cancer. OGSIVEO® (nirogacestat), approved in the United States for
the treatment of adult patients with progressing desmoid tumors who
require systemic treatment, is the Company’s first FDA-approved
therapy. SpringWorks also has a diversified targeted therapy
pipeline spanning solid tumors and hematological cancers, with
programs ranging from preclinical development through advanced
clinical trials. In addition to its wholly owned programs,
SpringWorks has also entered into multiple collaborations with
innovators in industry and academia to unlock the full potential
for its portfolio and create more solutions for patients in
need.
For more information, visit www.springworkstx.com and
follow @SpringWorksTx on X (formerly
Twitter), LinkedIn, and YouTube.
Contacts:Kim DiamondVice President,
Communications and Investor RelationsPhone: 203-561-1646Email:
kdiamond@springworkstx.com
Samantha Hilson SandlerSenior Director, Investor RelationsPhone:
203-461-5501Email: samantha.sandler@springworkstx.com
Grafico Azioni SpringWorks Therapeutics (NASDAQ:SWTX)
Storico
Da Gen 2025 a Feb 2025
Grafico Azioni SpringWorks Therapeutics (NASDAQ:SWTX)
Storico
Da Feb 2024 a Feb 2025